Neutralizing anti-SARS-CoV-2 antibodies
This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
1. An isolated anti-SARS-CoV-2 antibody or antigen-binding fragment thereof that binds specifically to a SARS-CoV-2 antigen, comprising three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region having the amino acid sequence of SEQ ID NO: 2.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the SARS-CoV-2 antigen comprises a Spike (S) polypeptide.
3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is capable of neutralizing a plurality of SARS-CoV-2 strains.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the anti-SARS-CoV-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of SEQ ID NO: 1 and a light chain variable region of SEQ ID NO: 2.
5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a multivalent antibody comprising (a) a first target binding site comprising three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region having the amino acid sequence of SEQ ID NO: 2 that specifically binds to an epitope within the S polypeptide, and (b) a second target binding site that binds to an epitope on a different epitope on the S polypeptide or a different molecule.
6. The antibody or antigen-binding fragment thereof of claim 5 , wherein the multivalent antibody is a bivalent or bispecific antibody.
7. The antibody or the antigen-binding fragment thereof of claim 1 , further comprising an Fc region or a variant Fc region.
8. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.
9. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a chimeric antibody, a humanized antibody, or humanized monoclonal antibody.
10. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a single-chain antibody, a Fab fragment, or a Fab2 fragment.
11. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and optionally a pharmaceutically acceptable carrier or excipient.
12. The pharmaceutical composition of claim 11 , further comprising a second therapeutic agent.
13. The pharmaceutical composition of claim 12 , wherein the second therapeutic agent comprises an anti-inflammatory drug or an antiviral compound.
14. A kit comprising the pharmaceutical composition of claim 11 for the diagnosis, prophylaxis, treatment, or combination thereof of a condition resulting from a SARS-CoV-2 infection.
15. A nucleic acid molecule encoding a polypeptide chain of the antibody or antigen-binding fragment thereof of claim 1 .
16. A vector comprising the nucleic acid molecule of claim 15 .
17. A cultured host cell comprising the nucleic acid molecule of claim 15 .
18. A method of preparing an antibody, or antigen-binding portion thereof, comprising:
obtaining the cultured host cell of claim 17 ;
culturing the cultured host cell in a medium under conditions permitting expression of a polypeptide encoded by the nucleic acid molecule and assembling of an antibody or fragment thereof; and
purifying the antibody or fragment from the cultured cell or the medium of the cell.
19. A kit comprising a pharmaceutically acceptable dose unit of the antibody or antigen-binding fragment thereof of claim 1 .
20. A kit for the diagnosis, prognosis or monitoring the treatment of SARS-CoV-2 infection in a subject, comprising: the antibody or antigen-binding fragment thereof of claim 1 ; and at least one detection reagent that binds specifically to the antibody or antigen-binding fragment thereof.
21. A method of neutralizing SARS-CoV-2 in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment thereof of claim 1 .
22. A method of treating a SARS-CoV-2 infection, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment thereof of claim 1 .
23. The method of claim 22 , further comprising administering to the subject a therapeutically effective amount of a second therapeutic agent or therapy.
24. The method of claim 23 , wherein the second therapeutic agent comprises an anti-inflammatory drug or an antiviral compound.
25. The method of claim 21 , wherein the antibody or antigen-binding fragment thereof is administered to the subject intravenously, subcutaneously, or intraperitoneally.
26. The method of claim 21 , wherein the antibody or antigen-binding fragment thereof is administered prophylactically or therapeutically.
27. A method for detecting the presence of SARS COV-2 in a sample comprising:
contacting a sample with the antibody or antigen-binding fragment thereof of claim 1 ; and
determining binding of the antibody or antigen-binding fragment to one or more SARS CoV-2 antigens,
wherein binding of the antibody to the one or more SARS CoV-2 antigens is indicative of the presence of SARS CoV-2 in the sample.